---
title: "Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis | IMUX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287900647.md"
description: "Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis | IMUX Stock News"
datetime: "2026-05-28T02:30:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287900647.md)
  - [en](https://longbridge.com/en/news/287900647.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287900647.md)
---

# Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis | IMUX Stock News

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis | IMUX Stock News

### Related Stocks

- [IMUX.US](https://longbridge.com/en/quote/IMUX.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)

## Related News & Research

- [Immunic Buy Rating: Vidofludimus Calcium’s Differentiated Efficacy and Safety Profile vs. BTK Inhibitors in Relapsing MS](https://longbridge.com/en/news/283709394.md)
- [Sobi to present new data on pegcetacoplan at ERA 2026](https://longbridge.com/en/news/288238139.md)
- [06:30 ETImmunic to Participate in Investor and Medical Conferences in May](https://longbridge.com/en/news/284746729.md)
- [Immunic Buy Rating: Undervalued Next-Generation Oral MS Therapy with Key Phase III Catalysts and Strategic Partnership Upside](https://longbridge.com/en/news/271838459.md)
- [Immunic Secures $200M Financing to Advance MS Programs](https://longbridge.com/en/news/275904161.md)